Abbott has received CE mark approval for next-generation dev selectscience.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from selectscience.net Daily Mail and Mail on Sunday newspapers.
Search jobs 09-Apr-2021 Abbott Receives CE Mark Approval for Next-Generation TriClip™ Device, Offering New Innovations for Tricuspid Heart Valve Repair
Abbott Receives CE Mark Approval for Next-Generation TriClip™ Device, Offering New Innovations for Tricuspid Heart Valve Repair
• New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve
• Next-generation therapy offers enhanced leaflet grasping feature and new clip sizes to fit each patient s complex tricuspid valve anatomy
• TriClip G4 makes treatment more customizable, expanding options for physicians seeking innovative transcatheter structural heart solutions
ABBOTT PARK, Ill., April 8, 2021 Abbott today announced it has received CE Mark for its next-generation TriClip™ Transcatheter Tricuspid Valve Repair System, the first-of-its-kind minimally invasive tricuspid hea
Abbott Receives CE Mark and Canadian Approval for Next-Generation TriClip Tricuspid Valve Repair Device
New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve
The new generation Abbott TriClip G4 device has gained European and Canadian approvals for transcatheter tricuspid valve repair (TTVR). The device is an iteration of the successful MitraClip device used for transcatheter mitral valve repairs.
April 8, 2021 Abbott today announced it has received European CE mark and Health Canada authorization this week for its next-generation TriClip Transcatheter Tricuspid Valve Repair (TTVR) System, a minimally invasive tricuspid heart valve repair device to treat tricuspid regurgitation (TR). The clip-based therapy, known as TriClip G4, is a non-surgical heart valve repair option specifically designed for the treatment of TR that allows physicians to tailor repair of the valve to each patient s unique anatomy.
Share this article
Share this article
ABBOTT PARK, Ill., April 8, 2021 /PRNewswire/ Abbott (NYSE: ABT) today announced it has received CE Mark for its next-generation TriClip™ Transcatheter Tricuspid Valve Repair System, the first-of-its-kind minimally invasive tricuspid heart valve repair device available in Europe to treat tricuspid regurgitation (TR). The clip-based therapy, known as TriClip G4, is a non-surgical heart valve repair option specifically designed for the treatment of TR, or a leaky tricuspid valve, that allows physicians to tailor repair of the valve to each patient s unique anatomy.
Often referred to as the forgotten valve because of historically limited treatment options, the tricuspid valve has three leaflets that control the flow of blood between the two chambers on the right side of the heart (right ventricle and right atrium). When those leaflets do not close properly, blood can flow in the reverse direction – known as regurgitation – forcing the